Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
87
Employees87
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
87
Employees87

CELC Key Statistics

Market cap
5.07B
Market cap5.07B
Price-Earnings ratio
-29.80
Price-Earnings ratio-29.80
Dividend yield
Dividend yield
Average volume
884.27K
Average volume884.27K
High today
$113.00
High today$113.00
Low today
$107.87
Low today$107.87
Open price
$110.13
Open price$110.13
Volume
683.12K
Volume683.12K
52 Week high
$120.32
52 Week high$120.32
52 Week low
$7.58
52 Week low$7.58

Stock Snapshot

With a market cap of 5.07B, Celcuity(CELC) trades at $108.00. The stock has a price-to-earnings ratio of -29.80.

During the trading session on 2026-01-30, Celcuity(CELC) shares reached a daily high of $113.00 and a low of $107.87. At a current price of $108.00, the stock is +0.1% higher than the low and still -4.4% under the high.

Trading activity shows a volume of 683.12K, compared to an average daily volume of 884.27K.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $120.32 and a low of $7.58.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $120.32 and a low of $7.58.

CELC News

Simply Wall St 1d
Assessing Celcuity Valuation After FDA Priority Review Milestone For Gedatolisib

Celcuity (CELC) has moved into focus after the FDA accepted its New Drug Application for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer, gran...

Assessing Celcuity Valuation After FDA Priority Review Milestone For Gedatolisib
Simply Wall St 3d
Celcuity Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDA - What's Changed

Celcuity Inc. recently announced that the FDA accepted for filing its New Drug Application for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer...

Celcuity Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDA - What's Changed
TipRanks 5d
Short Report: Celcuity short interest continues to grow

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-...

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.